Orthofix Medical Inc. (NASDAQ:OFIX) Receives $15.50 Consensus Price Target from Analysts

Shares of Orthofix Medical Inc. (NASDAQ:OFIX) have been assigned a consensus recommendation of “Hold” from the five research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $16.00.

A number of research analysts have recently issued reports on OFIX shares. Stifel Nicolaus dropped their price objective on Orthofix Medical from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a research note on Tuesday, April 21st. Barrington Research increased their price target on Orthofix Medical from $15.00 to $17.00 and gave the stock an “outperform” rating in a report on Monday. Wall Street Zen lowered shares of Orthofix Medical from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, TD Cowen reissued a “hold” rating on shares of Orthofix Medical in a research note on Thursday, May 21st.

Orthofix Medical Stock Performance

Shares of OFIX stock opened at $11.72 on Friday. The stock has a market capitalization of $473.72 million, a PE ratio of -7.76 and a beta of 0.71. The business’s 50 day simple moving average is $10.48 and its 200 day simple moving average is $12.29. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.87 and a quick ratio of 1.76. Orthofix Medical has a one year low of $8.85 and a one year high of $16.99.

Orthofix Medical (NASDAQ:OFIX) last issued its quarterly earnings results on Tuesday, May 5th. The medical device company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.16. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. The firm had revenue of $196.71 million for the quarter, compared to the consensus estimate of $196.40 million. As a group, research analysts forecast that Orthofix Medical will post -1.48 earnings per share for the current year.

Insider Transactions at Orthofix Medical

In other news, Director John B. Henneman III bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was acquired at an average cost of $12.26 per share, with a total value of $61,300.00. Following the transaction, the director directly owned 90,809 shares of the company’s stock, valued at approximately $1,113,318.34. This represents a 5.83% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Engine Capital Management, Lp bought 30,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was bought at an average price of $12.18 per share, for a total transaction of $365,400.00. Following the acquisition, the insider directly owned 3,848,573 shares of the company’s stock, valued at approximately $46,875,619.14. This represents a 0.79% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have purchased 189,896 shares of company stock valued at $2,293,970. 2.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Orthofix Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in OFIX. R Squared Ltd lifted its holdings in Orthofix Medical by 7.2% during the first quarter. R Squared Ltd now owns 13,518 shares of the medical device company’s stock worth $155,000 after acquiring an additional 904 shares during the period. Gabelli Funds LLC increased its position in shares of Orthofix Medical by 0.4% during the 4th quarter. Gabelli Funds LLC now owns 235,303 shares of the medical device company’s stock valued at $3,567,000 after purchasing an additional 1,000 shares during the last quarter. Raymond James Financial Inc. raised its stake in shares of Orthofix Medical by 1.5% during the 3rd quarter. Raymond James Financial Inc. now owns 66,812 shares of the medical device company’s stock worth $978,000 after purchasing an additional 1,000 shares during the period. Amundi boosted its holdings in shares of Orthofix Medical by 2.7% in the 4th quarter. Amundi now owns 41,527 shares of the medical device company’s stock worth $630,000 after buying an additional 1,086 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Orthofix Medical by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock worth $335,000 after buying an additional 1,213 shares during the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.